Q-omics provides the consensus-scored CER1 profile across patient tissues and cancer cell-line models. CER1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CER1 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, CER1 RNA expression shows 10,110 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, KIRC, and TGCT as cancer lineages where CER1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CER1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CER1 survival associations across molecular data types. CER1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CER1 RNA expression–survival associations across cancer types. High CER1 expression shows unfavorable associations in LIHC, LGG, MESO and ACC, but favorable associations in HNSC and KIRP. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LIHC as the clearest survival context for CER1 RNA expression.
This table summarizes CER1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CER1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CER1 shows lower tumor expression in KIRC, KIRP, BRCA, KICH and UCEC and higher tumor expression in COAD. The KIRC box plot shows higher CER1 RNA expression in normal versus tumor tissue (log2 FC = −0.300, t-test p < 0.001).
This table shows molecular features associated with CER1 in patient tissues and cancer cell lines. In patient samples, CER1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CER1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
